Jennifer L. Moseley

Incidence of Resistance in a Double‐Blind Study Comparing Lopinavir/Ritonavir Plus Stavudine and Lamivudine to Nelfinavir plus Stavudine and Lamivudine

Dale J. Kempf, Martin King, Barry Bernstein et al. · The Journal of Infectious Diseases · 2004 · 221 citations · Full text

Life Sciences, Pharmacokinetics, Pharmacotherapy +17

Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study

Devalingam Mahalingam, Grey Wilkinson, Kevin H. Eng et al. · Clinical Cancer Research · 2019 · 184 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma

Devalingam Mahalingam, Christos Fountzilas, Jennifer L. Moseley et al. · Cancer Chemotherapy and Pharmacology · 2017 · 94 citations

Medicine, Oncology, Pharmacology +14

Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies

Monica Mita, Alain C. Mita, Jennifer L. Moseley et al. · British Journal of Cancer · 2017 · 64 citations · Full text

Medicine, Oncology, Pharmacology +17

A study of REOLYSIN in combination with pembrolizumab and chemotherapy in patients (pts) with relapsed metastatic adenocarcinoma of the pancreas (MAP).

Devalingam Mahalingam, Christos Fountzilas, Jennifer L. Moseley et al. · Journal of Clinical Oncology · 2017 · 24 citations

Pharmacy, Oncology, Pharmacotherapy +17